Skip to main content

Sigilon Therapeutics, Inc. (SGTX)

NASDAQ: SGTX · IEX Real-Time Price · USD
5.81 -0.04 (-0.68%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap183.37M
Revenue (ttm)13.62M
Net Income (ttm)n/a
Shares Out31.57M
EPS (ttm)-3.32
PE Ration/a
Forward PE2.77
Dividendn/a
Ex-Dividend Daten/a
Volume37,645
Open5.79
Previous Close5.85
Day's Range5.61 - 5.88
52-Week Range4.33 - 54.32
Betan/a
AnalystsBuy
Price Target20.75 (+257.1%)
Est. Earnings DateNov 9, 2021

About SGTX

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits...

IndustryBiotechnology
IPO DateDec 4, 2020
Employees99
Stock ExchangeNASDAQ
Ticker SymbolSGTX
Full Company Profile

Financial Performance

In 2020, SGTX's revenue was $13.37 million, a decrease of -5.52% compared to the previous year's $14.16 million. Losses were -$54.61 million, 24.3% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for SGTX stock is "Buy." The 12-month stock price forecast is 20.75, which is an increase of 257.14% from the latest price.

Price Target
$20.75
(257.14% upside)
Analyst Consensus: Buy

News

Sigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

CAMBRIDGE, Ma., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Livin...

2 months ago - GlobeNewsWire

Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases

Company selected for oral presentation on mucopolysaccharidosis-1 (MPS-1), demonstrating potential of SIG-005 to provide sustained production of active human alpha-L-iduronidase in a preclinical model C...

2 months ago - GlobeNewsWire

Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development

CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Liv...

3 months ago - GlobeNewsWire

Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study

Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.

3 months ago - Zacks Investment Research

Here's Why Sigilon Therapeutics Stock Is Tanking Today

A clinical hold for the company's lead candidate wasn't what investors wanted to hear this morning.

3 months ago - The Motley Fool

Why Galectin Is Soaring And Sigilon Is Sinking Today

Galectin Therapeutics Inc. (NASDAQ: GALT) and Sigilon Therapeutics, Inc. (NASDAQ: SGTX) are among the biggest movers among biopharma stocks in early trading Friday. Galectin Spikes On Positive Data For ...

Other symbols:GALT
3 months ago - Benzinga

Serious Adverse Event Triggers FDA Clinical Hold On Sigilon Therapeutics' Hemophilia A Trial, Shares Drop

The FDA has instituted a clinical hold on Sigilon Therapeutics Inc's (NASDAQ: SGTX) Phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A.  The clinical hold was initiated...

3 months ago - Benzinga

Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Liv...

3 months ago - GlobeNewsWire

Biotech Losers In 2021 That Could Bounce Big In The Second Half

Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as ...

Other symbols:ATHACCXIIMRAIMVT
3 months ago - Benzinga

Sigilon Therapeutics Appoints Brooke Story, M.B.A., to its Board of Directors

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Liv...

4 months ago - GlobeNewsWire

Sigilon Therapeutics Appoints Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Liv...

4 months ago - GlobeNewsWire

Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Livi...

5 months ago - GlobeNewsWire

Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting

Presentations include initial results from preclinical studies of expanded pipeline programs in immune-mediated and metabolic diseases Presentations include initial results from preclinical studies of e...

5 months ago - GlobeNewsWire

Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

6 months ago - GlobeNewsWire

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

7 months ago - GlobeNewsWire

Sigilon Therapeutics' Fabry Disease Therapy Receives Orphan Drug Designation In US

The FDA has designated Orphan Drug Status to Sigilon Therapeutics Inc's (NASDAQ: SGTX) SIG-007 to treat Fabry disease. It is a rare genetic disorder caused by AGAL deficiency and the accumulation of spe...

7 months ago - Benzinga

Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

7 months ago - GlobeNewsWire

Sigilon Therapeutics to Present at Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

7 months ago - GlobeNewsWire

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at th...

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

7 months ago - PRNewsWire

Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021

CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

9 months ago - GlobeNewsWire

Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 Company plans to initiate a Phase 1/2 trial of SIG-005 in patients...

10 months ago - GlobeNewsWire

Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Opti...

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

10 months ago - GlobeNewsWire